A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
NCT ID: NCT02413229
Last Updated: 2018-12-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
151 participants
INTERVENTIONAL
2015-04-30
2016-01-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
NCT02618759
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
NCT05478499
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
NCT02267135
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
NCT03897088
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
NCT06875934
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DSXS1411
DSXS applied once a day for a total of 28 days.
DSXS1411
DSXS (Taro Pharmaceuticals Inc.)
Placebo
Placebo (vehicle) applied once a day for a total of 28 days.
Placebo
Placebo (vehicle) (Taro Pharmaceuticals Inc.)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DSXS1411
DSXS (Taro Pharmaceuticals Inc.)
Placebo
Placebo (vehicle) (Taro Pharmaceuticals Inc.)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of moderate to severe scalp psoriasis, defined by a Investigator's Global Assessment score of at least 3 at screening.
Exclusion Criteria
* Patients whose scalp and/or non-scalp psoriasis necessitates systemic or other concomitant topical therapies during the study.
* Has a scalp skin condition that would interfere with the diagnosis or assessment of plaque psoriasis of the scalp.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Pharmaceutical Industries, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novum Pharmaceutical Research Services
Role: STUDY_CHAIR
http://www.novumprs.com/contact
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DSXS 1411
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.